Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05409235 · ClinicalTrials.gov registry record · Phase 2
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
A Phase 2 study, sponsored by OcuTerra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT05409235 is a Phase 2 study that has completed, run by OcuTerra Therapeutics. The registered enrollment target is 225 participants.
The verdict
NCT05409235, a Phase 2 study, has completed, sponsored by OcuTerra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
Interventions
- DRUG Vehicle control
- DRUG OTT166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2023-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05409235
The ClinicalTrials.gov registry entry for NCT05409235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OcuTerra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle control is the first listed.
NCT05409235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05409235 about?
NCT05409235 is a clinical study titled "Nesvategrast (OTT166) in Diabetic Retinopathy (DR)". This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
What is the current status of trial NCT05409235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2022-07-29. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT05409235?
The interventions under investigation include: Vehicle control (DRUG), OTT166 (DRUG).
Who is sponsoring clinical trial NCT05409235?
This trial is sponsored by OcuTerra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.